These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27616637)

  • 61. Cytokine-dependent ex vivo expansion of early subsets of CD34+ cord blood myeloid progenitors is enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored.
    Ruggieri L; Heimfeld S; Broxmeyer HE
    Blood Cells; 1994; 20(2-3):436-54. PubMed ID: 7538350
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.
    Palau A; Garz AK; Diesch J; Zwick A; Malinverni R; Valero V; Lappin K; Casquero R; Lennartsson A; Zuber J; Navarro T; Mills KI; Götze KS; Buschbeck M
    Oncotarget; 2017 Dec; 8(70):115002-115017. PubMed ID: 29383137
    [TBL] [Abstract][Full Text] [Related]  

  • 63. BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells.
    Afreen S; Bohler S; Müller A; Demmerath EM; Weiss JM; Jutzi JS; Schachtrup K; Kunze M; Erlacher M
    Cell Death Dis; 2020 Jan; 11(1):8. PubMed ID: 31907357
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Strategy for erythroid differentiation in ex vivo cultures: Lentiviral genetic modification of human hematopoietic stem cells with erythropoietin gene.
    Cappellino LA; Kratje RB; Etcheverrigaray M; Prieto CC
    J Biosci Bioeng; 2017 Nov; 124(5):591-598. PubMed ID: 28688754
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
    Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
    Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Role of ASXL1 mutations in hematological disorders].
    Uni M
    Rinsho Ketsueki; 2019; 60(6):680-690. PubMed ID: 31281161
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
    Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
    J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gene expression profiling of human erythroid progenitors by micro-serial analysis of gene expression.
    Fujishima N; Hirokawa M; Aiba N; Ichikawa Y; Fujishima M; Komatsuda A; Suzuki Y; Kawabata Y; Miura I; Sawada K
    Int J Hematol; 2004 Oct; 80(3):239-45. PubMed ID: 15540898
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
    Uni M; Masamoto Y; Sato T; Kamikubo Y; Arai S; Hara E; Kurokawa M
    Leukemia; 2019 Jan; 33(1):191-204. PubMed ID: 29967380
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
    Fisher CL; Pineault N; Brookes C; Helgason CD; Ohta H; Bodner C; Hess JL; Humphries RK; Brock HW
    Blood; 2010 Jan; 115(1):38-46. PubMed ID: 19861679
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
    Braun TP; Estabrook J; Schonrock Z; Curtiss BM; Darmusey L; Macaraeg J; Enright T; Coblentz C; Callahan R; Yashar W; Taherinasab A; Mohammed H; Coleman DJ; Druker BJ; Demir E; Lusardi TA; Maxson JE
    Leukemia; 2023 Feb; 37(2):478-487. PubMed ID: 36526735
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
    Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
    Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
    Inoue D; Fujino T; Sheridan P; Zhang YZ; Nagase R; Horikawa S; Li Z; Matsui H; Kanai A; Saika M; Yamaguchi R; Kozuka-Hata H; Kawabata KC; Yokoyama A; Goyama S; Inaba T; Imoto S; Miyano S; Xu M; Yang FC; Oyama M; Kitamura T
    Leukemia; 2018 Jun; 32(6):1327-1337. PubMed ID: 29556021
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells.
    Leung CG; Xu Y; Mularski B; Liu H; Gurbuxani S; Crispino JD
    J Exp Med; 2007 Jul; 204(7):1603-11. PubMed ID: 17576776
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Depletion of polycomb repressive complex 2 core component EED impairs fetal hematopoiesis.
    Yu W; Zhang F; Wang S; Fu Y; Chen J; Liang X; Le H; Pu WT; Zhang B
    Cell Death Dis; 2017 Apr; 8(4):e2744. PubMed ID: 28406475
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
    Asada S
    Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
    Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W
    Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation.
    Wang W; Zhang X; Li Y; Shen J; Li Y; Xing W; Bai J; Shi J; Zhou Y
    Stem Cell Rev Rep; 2024 Jun; ():. PubMed ID: 38884929
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ASXL1/2 mutations and myeloid malignancies.
    Medina EA; Delma CR; Yang FC
    J Hematol Oncol; 2022 Sep; 15(1):127. PubMed ID: 36068610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.